2Witd S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes : estimates for the year 2000 and projections for 2030 [J]. Diabetes Care, 2004, 27(3) : 1 047
3Gutniak MK, Linde B, Hoist JJ, et al. Subcutaneous injection of the incretin hormone glucagous -like peptide 1 abolishes postprandial glycemia in NIDDM [J]. Dibetes Care,1994,17(9) :1 039
4Nauck MA, Wollschlager D, Wermer J et al. Effects of subcutaneous Glp - 1 [ 7 - 36 amide ] in NIDDM [ J ]. Dibetologia, 1996, 39(12) :1 546
5Vahl TP, Paty BW, Fuller BD et al. Effects of Glp - 1 - (7 - 36) - NH2,Glp - 1 - (7 -37), and Glp - 1 - (9 -36) - NH2 on intravenous glucose tolerance and glucose - induced insutin secretion in healthy humans. [ J]. Clin Endocrinol Metab ,2003,88 (13) :1 772
6Takei I, Kasatani T. Future therapy of diabetes mellitus [ J]. Biomed Pharmacother, 2004, 58( 10): 578
7Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon - like peptide 1 in elderly patients with type 2 diabetes [J]. Diabetes Care, 2003, 26( 10): 2 835
8Deacon CF, Knudsen LB, Madsen K et al. Dipeptidylpeptidase Ⅳ resistant analogues of glucagon - like peptide - 1 which have extended metabolic stability and improved biological activity [ J ] Diabetologia, 1998, 41 (3) : 271
9Leahy JL. Pathogenesis of type 2 diabetes mellitus [ J ]. Arch Med Res, 2005, 36(3) : 197
10Goke R, Fehmann HC, Linn T et al. Exantagonist at the glucagon -like peptide 1 - (7 -36 ) -amide receptor of insulin - secreting endin -4 is a high potency agonist and truncated exendin -(9-39) -amide an beta-cells [J]. J Biol Chem, 1993, 268(22) : 19 650
